INS and type 2 diabetes mellitus: The American Diabetes Association, the European Association for the Study of Diabetes and the Japan Diabetes Society currently recommend rapid‐acting insulin analogues as needed to avoid postprandial hyperglycaemia in people with type 2 diabetes mellitus (T2DM)1, 2; however, such additions can complicate therapy for patients, particularly if multiple injections are required, and can be associated with hypoglycaemic events and weight gain, leading to low adherence and poor compliance.3 Alternative treatment options are needed to address both fasting and postprandial blood glucose effectively.